Company / Operating Income per Share
Trevi Therapeutics, Inc. Operating Income per Share History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$0.51
FY2024
5-year range
-$1.80 / -$0.34
FY2020-FY2024
Trend
-47.5%
vs FY2023
Sector context
#75 of 201
Health Care
What the data says
At $-0.51, Trevi Therapeutics, Inc.'s operating income per share ranks #75 of 201 in the Health Care sector. Declined from $-0.46 to $-0.51 over the past 2 years.
Based on SEC 10-K filings.
-0.51 in FY2024.
Declined from $-0.46 to $-0.51 over the past 2 years.
Health Care sector context is included.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#75 of 201 in Health CareTop 37% of 201This company -$0.51 Sector average -$28.56
▼
+98.2% above sector average
Key checks
Key Insights
- In FY2024, operating income per share decreased 47.5% year-over-year.
- Ranks #75 out of 201 companies in the Health Care sector.
- Peak operating income per share was recorded in FY2023.
- Lowest operating income per share in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.91 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$0.51 | -47.5% |
| FY2023 | -$0.34 | +26.1% |
| FY2022 | -$0.46 | +67.4% |
| FY2021 | -$1.42 | +21.0% |
| FY2020 | -$1.80 | +20.8% |
| FY2019 | -$2.27 | +94.6% |
| FY2018 | -$42.06 | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026